Non-interventional study for the generation of long term safety and efficacy data of pasireotide s.c. in patients with Cushing's disease (Post-Authorization Safety Study)
Phase of Trial: Phase IV
Latest Information Update: 20 Mar 2018
At a glance
- Drugs Pasireotide (Primary)
- Indications Pituitary ACTH hypersecretion
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 20 Mar 2018 Interim results (n=99; Data cut off Oct 1, 2016) presented at The 100th Annual Meeting of the Endocrine Society
- 01 Mar 2018 Planned End Date changed from 1 Apr 2024 to 14 May 2024.
- 01 Mar 2018 Planned primary completion date changed from 1 Apr 2024 to 14 May 2024.